**Bone turnover in pregnancy, measured by urinary C-terminal telopeptide of type I collagen (CTX), is influenced by vitamin D supplementation and is associated with maternal bone health: Findings from the MAVIDOS trial**

Elizabeth M Curtis1\*, Camille Parsons1\*, Kate Maslin 1,2, Stefania D’Angelo 1, Rebecca J Moon 1,3, Sarah R Crozier 1, Fatma Gossiel4, Nicholas J Bishop5, Stephen H Kennedy6, Aris T Papageorghiou6, Robert Fraser7, Saurabh V Gandhi7, Ann Prentice 8, Hazel M Inskip 1,9, Keith M Godfrey 1,9, I Schoenmakers 10, M K Javaid 11, R Eastell4, C Cooper 1,9,11+ , N C Harvey 1,9+ and the MAVIDOS Trial Group

1. MRC Lifecourse Epidemiology Unit, University of Southampton, Southampton, UK (EMC, CP, KM, SD, RJM, SRC, HMI, KMG, CC, NCH)

2. School of Nursing and Midwifery, University of Plymouth, Devon, UK (KM)

3. Paediatric Endocrinology, University Hospitals Southampton NHS Foundation Trust, Southampton, UK (RJM)

4. Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK (FG, RE)

5. Academic Unit of Child Health, Sheffield Children’s Hospital, University of Sheffield, Sheffield, UK (NJB)

6. Nuffield Department of Women’s & Reproductive Health, John Radcliffe Hospital, University of Oxford, Oxford, UK (SHK, ATP)

7. Department of Obstetrics and Gynaecology, Sheffield Hospitals NHS Trust, University of Sheffield, Sheffield, UK (RF)

8. MRC Nutrition and Bone Health, Clifford Allbutt Building, University of Cambridge, Cambridge, UK (AP)

9. NIHR Southampton Biomedical Research Center, University of Southampton and University Hospital Southampton NHS Foundation Trust, Southampton, UK (HMI, KMG, CC, NCH)

10. Department of Medicine, Faculty of Medicine and Health Sciences, University of East Anglia, Norwich, UK (IS)

11. NIHR Oxford Biomedical Research Centre, University of Oxford, UK (MKJ, CC)

MAVIDOS Trial Group: N K Arden, A Carr, M Clynes, E M Dennison, M Z Mughal, SJ Woolford

\*EMC and CP are joint first authors; +NCH and CC are joint senior authors

**Corresponding author:**

Professor Cyrus Cooper

MRC Lifecourse Epidemiology Unit, Southampton General Hospital, Tremona Road, Southampton, UK

[cc@mrc.soton.ac.uk](mailto:cc@mrc.soton.ac.uk)

(+44) 23 8076 4032

**Sources of Support:**

This work was supported by grants from Arthritis Research UK, Medical Research Council (MRC) [4050502589 (MRC LEU)], Bupa Foundation, UK Royal Osteoporosis Society, National Institute for Health Research (NIHR) Southampton Biomedical Research Center (IS-BRC-1215-20004)), University of Southampton and University Hospital Southampton NHS Foundation Trust, and NIHR Oxford Biomedical Research Centre, University of Oxford. EC is supported by the Wellcome Trust (201268/Z/16/Z). AP is funded by the MRC (programme code U105960371). KMG is supported by the National Institute for Health Research (NIHR Senior Investigator (NF-SI-0515-10042), NIHR Southampton 1000DaysPlus Global Nutrition Research Group (17/63/154), the European Union (Erasmus+ Programme Early Nutrition eAcademy Southeast Asia-573651-EPP-1-2016-1-DE-EPPKA2-CBHE-JP and ImpENSA 598488-EPP-1-2018-1-DE-EPPKA2-CBHE-JP), the US National Institute On Aging of the National Institutes of Health (Award No. U24AG047867) and the UK ESRC and BBSRC (Award No. ES/M00919X/1). The work leading to these results was supported by the European Union’s Seventh Framework Programme (FP7/2007–2013), projects EarlyNutrition and ODIN under grant agreements numbers 289346 and 613977, and by the BBSRC (HDHL-Biomarkers, BB/P028179/1), as part of the ALPHABET project, supported by an award made through the ERA-Net on Biomarkers for Nutrition and Health (ERA HDHL), Horizon 2020 grant agreement number 696295. Members of the authorship contribute to the European Reference Network On Rare Bone Diseases. We are extremely grateful to Merck GmbH for the kind provision of the Vigantoletten supplement. Merck GmbH had no role in the trial execution, data collection, analysis or manuscript preparation. The authors had full access to all study data.

**Short running head:** Vitamin D supplementation in pregnancy and bone resorption

**Abbreviations list (if there are three or more):**

**25(OH)-vitamin D, 25(OH)D** 25-hydroxycholecalciferol, calcidiol

**1,25(OH)2D** 1,25-diydroxycholecalciferol, calcitriol

**24,25(OH)2D 24,25-** diydroxycholecalciferol

**CLIA** Chemiluminescent immunoassay

**CTX** C-terminal telopeptide of type I collagen

**DXA** Dual energy X-ray absorptiometry

**ELISA** Enzyme Linked Immunosorbent Assay

**FGF-23** Fibroblast growth factor-23

**MAVIDOS** The Maternal Vitamin D Osteoporosis Study

**MHRA** United Kingdom (UK) Medicines & Healthcare products Regulatory Agency

**NTX** N-terminal telopeptide of type 1 collagen

**OPG** Osteoprotegerin

**P1NP** N-terminal collagen extension propeptide

**PTH** Parathyroid Hormone

**PTHrp** Parathyroid hormone- related peptide

**RANKL** Receptor activator of NF-κB ligand

**Clinical Trial Registry number and website:** ISRCTN:82927713; EUDRACT:2007-001716-23

**Data sharing:** Data described in the manuscript (de-identified), code book, and analytic code will be made available upon request pending application to and approval of the corresponding author.

**Abstract**

*Background:*

The pattern of change in maternal bone turnover throughout pregnancy is poorly characterized.

*Objective:*

We investigated changes across pregnancy in a marker of maternal bone resorption, urinary C-terminal telopeptide of type I collagen (CTX), the influence of gestational vitamin D supplementation, and associations between CTX and maternal postnatal bone indices.

*Design:*  
The Maternal Vitamin D Osteoporosis Study (MAVIDOS) is a randomized, double-blind, placebo-controlled trial of 1000 IU/day cholecalciferol vs placebo from 14 weeks’ gestation to birth. Maternal second void urinary α- and β-CTX were measured (Enzyme Linked Immunosorbent Assay, ELISA) at 14 and 34 weeks’ gestation; DXA was performed within 2 weeks post-partum. Mann-Whitney rank sum, Spearman’s rank correlation and linear regression were used to compare median CTX values within and between groups from early to late pregnancy, and associations with maternal bone outcomes.

*Results:*

372 women had CTX and 25(OH)-vitamin D measured in early and late pregnancy. CTX at 14 and 34 weeks’ gestation were correlated in both placebo (r=0.31) and cholecalciferol (r=0.45) groups (p<0.0001). Median CTX(g/mmol creatinine) increased from 14 to 34 weeks’ gestation in both groups (n=372 total) [placebo (n=188) 223.6 to 449.7; cholecalciferol (n=184) 222.3 to 419.3; p=0.03 for placebo vs cholecalciferol difference in CTX at 34 weeks’ gestation]. The conditional increase in CTX(SD) from early to late pregnancy was greater in the placebo group (n=188) than in the cholecalciferol group (n=184) [placebo, mean(SD) 0.16(0.92); cholecalciferol, -0.16(1.06); p difference<0.01]. Higher CTX at 34 weeks’ gestation was associated, similarly in both groups, with lower maternal total hip and lumbar spine bone mineral content (BMC) and bone mineral density, e.g. lumbar spine BMD [-0.02g/cm2/SD increase in CTX; 95%CI: -0.027, -0.002; p=0.02, n=283].

*Conclusions:*

Maternal urinary CTX, a bone resorption marker, rises through pregnancy, though to a lesser degree with gestational cholecalciferol supplementation, and is inversely associated with maternal bone mass post-partum.

**Key words:** osteoporosis; epidemiology; vitamin D; bone turnover; pregnancy; CTX; DXA

**Introduction**

The human fetal skeleton begins to mineralise between the 8 and 12 weeks’ gestation when primary ossification centers form in the vertebrae and long bones (1). Approximately 30g of calcium are required in total for its development, 80% of which is accrued in the 3rd trimester. Maternal calcium homeostasis adapts to meet the calcium demands of the developing fetus (1-3), particularly through increased intestinal absorption and renal reabsorption of calcium. The maternal skeleton’s role in supplying the fetus, and how it might respond to interventions such as vitamin D supplementation, are not well defined, because of the difficulty in using dual energy X-ray absorptiometry (DXA), which involves ionising radiation, in pregnancy. Biochemical markers of bone turnover offer a non-invasive method of monitoring changes in bone resorption or formation during pregnancy (4), and provide some insight into the impact of pregnancy on maternal bone and its contribution to fetal development. There are two groups of bone turnover markers: markers of bone formation (such as N-terminal collagen extension propeptide (P1NP), bone alkaline phosphatase) and markers of resorption (such as C-terminal cross-linking telopeptide of type 1 collagen (CTX), N-terminal telopeptide of type 1 collagen (NTX), deoxypyridinoline, hydroxyproline). In the vitamin D deficient state, plasma calcium concentrations may be reduced with a consequent rise in parathyroid hormone, leading to increased bone resorption (5). Indeed at the population level, there is evidence of inverse associations between 25(OH)-vitamin D concentrations and markers of bone resorption such as CTX (6-9). However, few studies have investigated these relationships across normal pregnancies, or the influence of vitamin D supplementation (10-17).

The MAVIDOS trial of vitamin D supplementation in pregnancy (of which the primary aim was to investigate the effect of gestational cholecalciferol supplementation on offspring bone mass) provides an opportunity to study the impact of this supplement on a marker of maternal bone resorption (CTX) and maternal post-partum bone indices (18, 19). As the basis for this post hoc analysis, we hypothesised that vitamin D supplementation in pregnancy would result in reduced osteoclastic bone resorption, and thus that we would observe: a) an inverse association between vitamin D supplementation (or 25(OH)-vitamin D concentration) and CTX concentrations, and b) an inverse association between maternal CTX concentrations and measures of maternal post-partum bone mass.

**Subjects and Methods**

*The Maternal Vitamin D Osteoporosis Study (MAVIDOS)*

MAVIDOS was a multicenter, double-blind, randomized, placebo-controlled trial of vitamin D supplementation in pregnancy. The primary outcome was neonatal bone mass. A detailed description of the study methods (18) and primary findings have been published previously (19).

Briefly, women attending one of three UK hospitals [University Hospital Southampton NHS Foundation Trust, Southampton, UK; Oxford University Hospitals NHS Foundation Trust, Oxford, UK; Sheffield Teaching Hospitals NHS Foundation Trust (University of Sheffield), Sheffield, UK] for early pregnancy ultrasound screening (11-14 weeks’ gestation) between 6th October 2008 and 11th February 2014 were invited to participate in the study (19, 20). Inclusion criteria were: age over 18 years, singleton pregnancy, and gestation less than 17 weeks based on last menstrual period and ultrasound measurements. Women with known metabolic bone disease, renal stones, hyperparathyroidism or hypercalciuria; those taking medication known to interfere with fetal growth, those with fetal anomalies on ultrasonography and women already using >400IU/day vitamin D supplementation were excluded. A screening blood sample was obtained and analysed on the local NHS platform [all three laboratories (Southampton, Oxford and Sheffield) participate in DEQAS vitamin D quality assurance system (http://www.deqas.org/)]. Women with 25(OH)D between 25 and 100nmol/l and serum calcium <2.75mmol/l were eligible to enrol fully in the study. Participants were randomized in a double-blind design to either cholecalciferol 1000 IU/day or matched placebo [Merck KGaA, (Darmstadt, Germany)/ Sharp Clinical Services (Crickhowell, UK; previously DHP-Bilcare)], which was commenced before 17 weeks’ gestation. All participants received standard antenatal care and could continue self-administration of dietary supplements containing up to 400 IU/day vitamin D. Data from Southampton participants were used in the current analysis as CTX was not measured in Oxford and Sheffield participants.

*Maternal assessments during pregnancy*

Prior to commencing the study medication, and again at 34 weeks’ gestation, the women attended the hospital for a detailed assessment of diet (including supplement use), lifestyle (smoking, physical activity, employment) and health (past medical history, current medication use) using interviewer-led questionnaires. Ethnic group was self-reported by the participant as “White, Black Caribbean, Black African, Black Other, Indian, Pakistani, Bangladeshi, Chinese, Other Asian group or Other (specify)”. This was then categorized as White or non-White. Anthropometric measurements included height, measured to the nearest 0.1cm using a stadiometer (Seca, Birmingham, UK), and weight, assessed to the nearest 0.1kg using calibrated electronic scales (Seca, Birmingham, UK).

*Assessment of 25(OH)-vitamin D and CTX*

On the day that the study medication was dispensed and at 34 weeks’ gestation, a non-fasted venous blood sample was obtained, and serum stored at -80°C. 25(OH)-vitamin D [25(OH)D] was assessed by chemiluminescent immunoassay (CLIA) (Liaison automated platform, Diasorin, Minnesota, USA). All samples were analysed in a single batch at the end of the study at MRC Human Nutrition Research, Cambridge, UK. Details of assay performance and quality control through participation in DEQAS, NIST and NEQAS are given elsewhere (21, 22).

Participants were asked to provide a second-void early morning urine sample to measure urine α and β-C-terminal telopeptide of type I collagen (CTX) on the day the study medication was started (around 14 weeks’ gestation), and again at 34 weeks’ gestation. Owing to the diurnal variation in CTX, in addition to the practical difficulties of obtaining a fasted blood sample from pregnant women, second-void early morning urine collection by the participant at home was selected as the most appropriate measure of bone resorption. All samples were stored at -70oC and those from Southampton participants were sent in a batch for measurement by ELISA (Immunodiagnostic Systems, Boldon, UK) at the Academic Unit of Bone Metabolism, University of Sheffield, Sheffield, UK. Total CTX (sum of α and β forms) is expressed as a ratio to urine creatinine (µg/mmol) (23). The assay had an inter-assay coefficient of variation of 6% (24).

*Maternal and neonatal DXA*

Mothers and neonates underwent DXA assessment ; mothers underwent DXA at the lumbar spine and hip sites, neonates at the whole body and lumbar spine sites (instrument at the Southampton center: Hologic Discovery, Hologic Inc, Bedford, MA, USA) within 2 weeks of delivery. The instrument underwent daily quality control. To maximise the scan quality, infants were undressed, clothed in a standard towel, fed, and pacified before the assessment. The total radiation dose was estimated to be 0.04 mSv, equivalent to about 7 days’ exposure to background radiation in the UK. All DXA images were reviewed for movement artefacts and quality by two operators who were blinded to treatment allocation.

*Ethics*

The trial was approved by the Southampton and South West Hampshire Research Ethics Committee (07/H0502/113). MAVIDOS was registered prospectively (ISRCTN:82927713; EUDRACT:2007-001716-23); full approval from the United Kingdom (UK) Medicines & Healthcare products Regulatory Agency (MHRA) was granted, and written, informed consent was obtained from all participants.

*Statistics*

Women who had urinary CTX and 25(OH)D measured at either 14 and 34 weeks’ gestation, had not taken cholecalciferol supplements of greater than 400 IU daily in addition to the study intervention and who delivered a liveborn infant, were included in the analysis. All outcomes were assessed for normality using visual inspection. Maternal characteristics in the placebo and vitamin D supplemented groups were documented. Comparisons between median CTX concentrations in the placebo and cholecalciferol supplemented groups in early pregnancy (around 14 weeks’ gestation) and late pregnancy (34 weeks’ gestation) were made using the Mann-Whitney Rank Sum test. In order to avoid problems from regression to the mean and correlation between baseline value and change, early and late pregnancy CTX were summarised into a change in CTX variable, calculated as the residual from the regression of the later value on the earlier, differences between groups were tested using a t-test (25). This change in CTX variable was then used as an outcome variable in linear regression to explore maternal factors associated with change. Change in CTX was also used as a predictor in regression analyses examining associations between maternal CTX and neonatal bone indices.Spearman’s correlation was used to test associations between CTX in early pregnancy and late pregnancy, and between CTX (in early or late pregnancy) and maternal serum 25(OH)D measurements (in early or late pregnancy).

The distribution of CTX in early and late pregnancy was positively skewed and was therefore transformed and standardised using a Fisher-Yates Transformation for inclusion in regression analyses. Fisher-Yates transformed CTX values are used as a predictor in regression analysis with DXA-assessed bone outcomes ; beta coefficients represent change in bone outcome per 1 SD increase in CTX. In order to remove the additional influence of season on 25(OH)D concentrations, further analyses included adjustment for season of birth, using UK Meteorological Office classifications were used; Winter (December-Feb), Spring (March-May), Summer (June-August), Autumn (September-November). Covariates identified as associated with maternal CTX concentrations and known to be associated with bone mass were included in CTX-bone regression models. All analyses were performed in Stata v14 (Statacorp, College Station, Texas, USA).

**Results**

*Characteristics of the participants*

965 women recruited to the MAVIDOS trial remained in the study until delivery, and of these 630 had CTX measured in either early (n = 493) or late pregnancy (n = 498). 372 women had a CTX measurement at both timepoints (placebo group, n = 188, cholecalciferol supplemented group, n = 184), as shown in **Supplementary Figure 1**. The characteristics of the mothers with a measurement of urine CTX in early or late pregnancy are summarised in **Table 1**, demonstrating a mean age of 30.4 years, 95.0% of self-reported White ethnicity and 44.5% nulliparous. There was no evidence of selective drop-out (as shown in **Supplementary Table 1**, comparing the participants of this sub-study with the overall MAVIDOS trial) and thus in this subgroup analysis baseline characteristics appeared comparable between the mothers randomized to placebo or cholecalciferol. Baseline maternal 25(OH)D concentration (measured at recruitment, 14 weeks’ gestation) was similar in both groups. At 34 weeks’ gestation mean maternal 25(OH)D concentration was significantly higher in the cholecalciferol supplemented group [66.0 nmol/l (SD 20.4)] than in those who received placebo [42.5 nmol/l (SD 20.6); p < 0.0001].

*Maternal urinary CTX in early and late pregnancy*

As demonstrated graphically in **Figure 1**, both early and late pregnancy urinary CTX were in a positively skewed distribution: a few women had very high CTX measures (> 1500 g/mmol creatinine). In both the placebo and 1000 IU/day cholecalciferol supplemented mothers, urinary CTX increased markedly from 14 to 34 weeks’ gestation [median 14 and 34 week CTX: placebo group, 223.8 and 445.3 g/mmol creatinine; cholecalciferol supplemented group, 217.5 and 420.0 g/mmol creatinine; (both p-difference < 0.0001)], as shown in **Table 2**. Median CTX at 34 weeks’ gestation tended to be greater in the placebo group compared with the cholecalciferol supplemented group (mean difference 25.3 g/mmol; p=0.06). Restricting the analysis to women with CTX measures in early and late pregnancy (n=372) led to greater observed differences in median CTX at 34 weeks’ gestation (30.4 g/mmol greater in the placebo group than the cholecalciferol supplemented group (p=0.03), also shown in **Table 2**. The conditional increase in CTX(SD) from early to late pregnancy was greater in the placebo group than in the cholecalciferol group [placebo, mean(SD) 0.16(0.92); cholecalciferol, -0.16(1.06); p difference<0.01]. Note that the negative conditional change in CTX in the cholecalciferol group is relative to the overall distribution of standardised conditional change in CTX so still represents a rise: both groups demonstrated a large, positive absolute increase in CTX (Placebo, median percentage change from early to late pregnancy was 111.1% (IQR 47.1, 210.9); cholecalciferol supplemented, 88.8% (IQR 25.9, 183.1)). When stratified by baseline 25(OH)-vitamin D status in early pregnancy [sufficient, ≥50nmol/l; or insufficient, below 50nmol/l], classified according to the 2011 report on dietary requirements for calcium and vitamin D from the Institute of Medicine (IOM)(2)), a threshold effect was observed. Women with vitamin D insufficiency at baseline in the placebo group had a greater conditional increase in CTX (0.28 SD, n=126) than in the cholecalciferol supplemented group (-0.15SD, n=123), p difference <0.01). In women with vitamin D sufficiency, similar conditional increases were observed in the placebo and cholecalciferol supplemented groups, as shown in **Table 2.**

*Maternal factors associated with CTX in early and late pregnancy*

**Table 3** documents the univariate associations between maternal characteristics and CTX concentrations in early or late pregnancy and with conditional change in CTX. Greater maternal age, parity and height were associated with lower CTX in early and late pregnancy. Cholecalciferol supplementation (1000 IU/day) from 14 weeks’ gestation was associated with -0.18 SD lower late pregnancy CTX compared with those who received placebo [95% CI -0.35, -0.001 (p = 0.05)]. There was evidence of associations between lower conditional change in CTX from early to late pregnancy and: lower BMI, greater baseline 25(OH)D, and cholecalciferol supplementation (-0.32SD conditional change in CTX compared to those who received placebo [95% CI -0.52, -0.11, p=0.002]).

*Associations between early and late pregnancy urinary CTX and maternal serum 25(OH)D*

There were modest correlations between early and late pregnancy CTX in both the placebo and treatment groups (placebo group r=0.31, treatment group r=0.45, both p<0.0001), **Supplementary Table 2**. Indeed, both early and late pregnancy 25(OH)D were also correlated, with evidence of a greater magnitude of correlation in the placebo group (r=0.36, p<0.0001) than in the cholecalciferol supplemented group (r=0.22, p=0.0003). No major correlations were demonstrated between early or late pregnancy serum 25(OH)D measurements and CTX measures. In the UK, season is strongly associated with maternal 25(OH)D in pregnancy.(19) CTX concentrations by season are presented in **Supplementary Table 3**, demonstrating little evidence for any seasonal effect.

In multivariate regression analyses adjusting for season of delivery (**Table 4**) we observed a trend towards modest inverse associations between late pregnancy maternal 25(OH)D and CTX in late pregnancy [in both groups combined, -0.004 SD/nmol/L greater 25(OH)D (95%CI-0.008, -0.001), p=0.056 and also with conditional change in CTX [SD/ nmol/l greater 25(OH)D, p=0.001. Associations between early pregnancy 25(OH)D and conditional change in CTX were observed, but were less robust (p=0.049). Adjustment for maternal age, smoking, parity, BMI and height (factors which were associated with CTX measures) did not materially alter the observed trends.

*Maternal CTX in late pregnancy, conditional change in CTX, and maternal postpartum bone heath*

In the 283 mothers with a late pregnancy measure of urine CTX and postpartum DXA, greater maternal urinary CTX at 34 weeks’ gestation was associated with lower maternal post-partum lumbar spine and total hip bone mineral content (BMC) and areal bone mineral density (aBMD), following adjustment for maternal age, parity, smoking and BMI in early pregnancy (in the groups combined). These associations appeared more robust in the cholecalciferol than in the placebo group and CTX-bone associations are summarised in **Table 5** and **Figure 2** (groups combined). The direction of associations with conditional change in CTX (**Table 5**) followed a similar but non-significant pattern and were substantially attenuated compared with those for LP CTX. Additional adjustment for maternal height attenuated the observed relationships (**Supplementary Tables 4a and b**).

***Conditional change in CTX, and neonatal bone indices***

321 mother – neonate pairs had a measure of early or late pregnancy maternal CTX and a neonatal whole body or lumbar spine DXA. The characteristics of the neonates are presented in **Supplementary Table 5**. No differences in neonatal anthropometry or DXA characteristics were observed between the placebo and cholecalciferol supplemented groups. On regression analyses (**Table 6**) greater maternal conditional change in CTX was associated with greater neonatal total body and total spine area, BMC and aBMD (adjusted for neonatal sex, age at DXA scan and gestational age at delivery). The magnitude and direction of associations was similar between the placebo and cholecalciferol supplemented groups, no interaction was observed between conditional change in CTX and randomisation group.

**Discussion**

In this post-hoc analysis of the MAVIDOS randomized controlled trial (RCT), we have demonstrated that maternal gestational cholecalciferol supplementation is associated with a smaller gestational increase in bone resorption markers compared with placebo. Whilst maternal urinary CTX almost doubled from 14 weeks’ to 34 weeks’ gestation in both vitamin D supplemented and placebo groups, the conditional increase in CTX from early to late pregnancy was lower in the cholecalciferol supplemented compared with the placebo group, with greater differences in conditional increase in CTX between the groups observed in vitamin D insufficient women. Furthermore, late pregnancy CTX was inversely associated with post-partum measures of maternal bone from DXA.

Our observation of increasing markers of bone resorption throughout pregnancy is replicated in other smaller studies, in which bone resorption markers have been shown to rise markedly through gestation, whilst markers of bone formation tend to be low in early pregnancy, reaching normal values by term, such that there is a net resorptive state in late pregnancy (10-17, 27). Studies of maternal bone mass throughout pregnancy and the post-partum period support this, showing that BMD declines by a small amount (between 2% and 5%at both trabecular (28) and cortical sites in the axial and peripheral skeleton (29), but importantly, pregnancy does not have a negative impact on bone health in later life (30). Both circadian (peaking in the early morning) and seasonal (peaking during winter months) variations in bone resorption markers have been observed (7, 31). Vitamin D has been proposed to play a role in this seasonal variation. Again, in keeping with our findings, several studies have demonstrated a negative association between 25(OH)D status and markers of bone resorption, in both non-pregnant and pregnant women (6-9). Our observation that greater conditional increases in CTX were associated with greater neonatal bone mass is in keeping with a previous study from our group using the Southampton Women’s Survey cohort. Greater maternal bone loss in pregnancy (as measured by calcaneal ultrasound) was shown to be associated with increased bone mineral density in their babies (32), consistent with associations between maternal bone resorption and transplacental calcium transfer to the developing fetus.

The link, however, between maternal vitamin D and its modulation of calcium transfer to the fetus is less clear. Circulating 1,25(OH)2D (calcitriol) increases during pregnancy with (most importantly) the maternal kidney and also possibly the placenta providing the necessary 1-hydroxylase activity (11, 16, 33). Increased 1,25(OH)2D is thought to contribute to greater maternal intestinal calcium absorption (34). Several factors are known to contribute to the regulation of the balance between maternal and fetal bone formation and resorption (osteoblast and osteoclast activity), including parathyroid hormone (PTH) and parathyroid hormone- related peptide (PTHrp) (35-37), receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG), Sclerostin and fibroblast growth factor-23 (FGF-23), the Wnt pathway, oestrogens and prolactin (38). It is, therefore, unlikely that the study of one potential mediating factor (maternal serum 25(OH)D concentrations), and one measure of bone resorption (urinary CTX), is likely to provide conclusive information about the system, though it does provide an important step towards our understanding of this complex process. Indeed, the European Food Safety Authority has identified the associations between vitamin D, bone turnover markers and bone health as a current knowledge gap, as outlined in their 2016 scientific opinion paper (39).

To our knowledge, MAVIDOS represents the first opportunity to study vitamin D and pregnancy bone markers in an interventional setting. The mechanism for the observed inverse relationship between maternal cholecalciferol supplementation vs placebo and CTX concentrations could be related to greater calcium availability from maternal intestinal absorption for the developing fetus in mothers with improved 25(OH)D status, reducing the requirement for the release of calcium by maternal bone resorption. Our findings that higher maternal serum 25(OH)D concentration in late pregnancy is associated with lower late pregnancy CTX, after adjustment for season, and that women with vitamin D insufficiency in early pregnancy had greater conditional increases in CTX throughout pregnancy, supports this hypothesis. Studies of calcium and vitamin D in pregnant women provide supportive evidence for the resulting notion that maternal 25(OH)D status in late pregnancy is important in regulating maternal bone turnover to ensure calcium availability for the developing fetus. One previous RCT of calcium supplementation in pregnancy showed that daily consumption of a 1100 mg calcium supplement led to a 15% reduction in urinary NTX during the second and third trimesters (40). A prospective cohort showed that higher calcium intake in late pregnancy was associated with reduced bone resorption, with greater effects in winter, when vitamin D mediated calcium absorption is less (9). Other longitudinal studies of maternal pregnancy 25(OH)D status demonstrated that vitamin D repletion was associated with lower markers of bone resorption. In two small studies (n=47 and n=60) of pregnant women and healthy non-pregnant controls, greater 25(OH)D status, and greater levels of the vitamin D metabolites [1,25(OH)2D, 24,25(OH)2D] tended to be associated with lower bone resorption markers (serum NTX and CTX respectively) in the second and third trimesters and post-partum period, whilst no correlation between 25(OH)D and bone resorption markers was seen in the non-pregnant controls (6, 8). In non-pregnant women, a high bone turnover in those who are vitamin D deficient has been observed, with vitamin D supplementation attenuating this effect in some studies (41) but not others (42, 43).

CTX, released by osteoclastic resorption of bone, is significantly correlated with lower total hip BMD, distal radius BMD and lumbar spine BMD and poorer bone indices assessed by pQCT and histology (44-46). Our finding that greater urinary CTX in late pregnancy was associated with lower lumbar spine and hip BMC and BMD is in keeping with this observation. Interestingly the associations were of consistent direction but attenuated with conditional change in CTX which may reflect lower statistical power given the smaller cohort with measures at both timepoints or potentially that the absolute value in late pregnancy rather than change in concentrations is the more important factor. Notably, although the magnitude of the associations between CTX and bone measures were attenuated after adjustment for maternal height, this was a modest effect on aBMD, suggesting CTX-aBMD relationships at least partly independent of linear skeletal size.

*Limitations*

Our study had some limitations, the first being that, as a result of ethical stipulations, participants with 25(OH)D concentrations less than 25mmol/L at screening at 12 weeks of gestation could not be included. However, vitamin D deficiency has developed in a proportion of women by gestational week 34, particularly in the placebo group and those that with winter deliveries. Our findings may also not be relevant to non-White populations, as our study did not include many women who were not of self-reported White ethnicity. Additionally, we could not exclude the possibility that some participants were taking vitamin D in addition to the study drug, though reported supplement use did not differ between groups at baseline interview. Furthermore, as a result of the primary trial design, we were unable to characterize dietary calcium intake in detail, and assays of vitamin D metabolites (1,25(OH)2 vitamin D, 24,25(OH)2 vitamin D), PTH and PTHrp were not available, meaning a comprehensive assessment of maternal factors determining bone turnover could not be made. Limitations regarding the use of CTX as a marker of bone resorption should also be recognised including its circadian rhythm and relationship with food intake (though early morning, second void urine was used to minimise this variation). We were not able to adjust fully for hemodilution in pregnancy (which may also impact upon serum 25(OH)D levels)(47) and individual changes in maternal glomerular filtration rate, but did use the CTX value relative to creatinine to account for renal function (13). The assay used in this study does not distinguish between the different isoforms of CTX.CTX in particular is predominantly released from growing fetal bone and may cross the placenta. One study estimated that approximately 9% CTX and 2% of CTX in the mother’s urine in late pregnancy may be coming from the fetal skeleton(48); therefore, it is not possible to quantify the fetal contribution to the mother’s urinary CTX. As the participants were recruited in early pregnancy, pre-pregnancy DXA scans could not be performed. Therefore, we did not have the opportunity to explore changes in BMC and BMD, and its relationship with CTX, from pre-pregnancy to postpartum. Maternal breastfeeding is known to play a large role in determining levels of bone resorption and postpartum BMD, particularly at trabecular sites (49); lumbar spine BMD has been shown to decline by a mean of 5-10% during exclusive breastfeeding (49). Though mothers underwent DXA within 2 weeks postpartum, the number of days spent breastfeeding prior to DXA assessment may be important but these data were not available. Finally, it should be acknowledged that this is a sub-analysis of an RCT, so whilst the differences in CTX between groups and associations with bone indices are biologically plausible and consistent with existing medical literature, they should be recognised as post hoc and require replication.

In conclusion, we have shown that maternal urinary CTX rises from early to late pregnancy, with the magnitude of this rise appearing to be reduced by gestational cholecalciferol supplementation, and is inversely associated with maternal bone mass post-partum. These findings are consistent with a protective effect of gestational vitamin D supplementation on maternal bone health and inform our understanding of bone resorption in pregnancy and the potential relationship with vitamin D metabolism. Long-term follow-up of both mothers and offspring, with repeat assessments of bone indices, will enable us to determine better the lasting impact of cholecalciferol supplementation in pregnancy.

**Acknowledgements**

*Conflicts of Interest Statement*

E. Curtis reports honoraria/travel support from UCB, Eli Lilly, Pfizer and Amgen outside the submitted work. R. Moon has nothing to disclose. S D’Angelo has nothing to disclose. S. Crozier has nothing to disclose. N. Bishop reports remuneration from Internis Pharmaceuticals Ltd, outside the submitted work. S. Gopal-Kothandapani has nothing to disclose; S. Kennedy has nothing to disclose. A. Papageorghiou reports grants from Arthritis Research Council, during the conduct of the study. R. Fraser has nothing to disclose. S. Gandhi has nothing to disclose. I. Schoenmakers has nothing to disclose. A Prentice has nothing to disclose. H. Inskip reports grants from Medical Research Council, Arthritis Research UK, European Union’s Seventh Framework Programme, during the conduct of the study; and while not directly receiving funding from other bodies, members of her team have received funding from the following companies from other work: Danone, Nestec, Abbott Nutrition. K. Godfrey reports reimbursement for speaking at Nestle Nutrition Institute conferences, grants from Abbott Nutrition & Nestec, outside the submitted work; in addition, K. Godfrey has a patent Phenotype Prediction pending, a patent Predictive Use of CpG Methylation pending, and a patent Maternal Nutrition Composition pending, not directly related to this work. M.K. Javaid reports personal fees from Stirling Anglia, Consilient Health and Internis, outside the submitted work. R. Eastell reports grants and personal fees from Amgen, grants from Department of Health, grants from AstraZeneca, grants, personal fees and non-financial support from Immunodiagnostic Systems, grants from ARUK/MRC Center for Excellence in Musculoskeletal Ageing Research, grants from National Institute for Health Research, grants from MRC/AZ Mechanisms of Diseases Call, grants from MRC, grants and personal fees from Alexion, grants and other from National Osteoporosis Society, grants, personal fees and other from Roche, personal fees from Otsuka, Novartis, Merck, Bayer, Johnson & Johnson, Fonterra Brands, Janssen Research, personal fees and other from Eli Lilly, personal fees from Ono Pharma, Alere (Unipath), Chronos, personal fees and other from CL Biosystems, other from European Calcified Tissue Society, IOF CSA, personal fees from Teijin Pham Limited, other from ASBMR, personal fees from D-STAR, personal fees from GSK Nutrition, outside the submitted work. N. Arden has received honoraria, held advisory board positions (which involved receipt of fees), and received consortium research grants, respectively, from: Merck, grants from Roche, personal fees from Smith & Nephew, Nicox, Flexion, grants from Bioiberica, Novartis, and personal fees from Bioventus and Freshfields, outside the submitted work. A. Carr has nothing to disclose. M. Clynes has nothing to disclose. E. Dennison has nothing to disclose. M.Z. Mughal has nothing to disclose. D. Reid has nothing to disclose. S. Woolford has nothing to disclose. C. Cooper reports personal fees from ABBH, Amgen, Eli Lilly, GSK, Medtronic, Merck, Novartis, Pfizer, Roche, Servier and Takeda, outside the submitted work. N. Harvey reports personal fees, consultancy, lecture fees and honoraria from Alliance for Better Bone Health, AMGEN, MSD, Eli Lilly, Servier, Shire, UCB, Consilient Healthcare, Kyowa Kirin and Internis Pharma, outside the submitted work.

*Author contributions*

EMC and NCH designed the research, EMC, KM, RJM and NCH wrote the paper. FG and RE, alongside IS and AP undertook or advised upon the laboratory analyses. CP, SD, SRC and HMI performed the statistical analysis. NJB, SHK, ATP, RF, SVG, KMG, MKJ oversaw the MAVIDOS trial at the Oxford, Sheffield and Southampton sites. NCH and CC supervised the study and the preparation of the manuscript. CC had primary responsibility for final content. All authors contributed to the preparation and have read and approved the final version.

**References**

1. Kovacs CS. Calcium and bone metabolism in pregnancy and lactation. J Clin Endocrinol Metab. 2001;86(6):2344-8.

2. Givens MH, Macy IG. The chemical composition of the human fetus. Journal of Biological Chemistry. 1933;102(1):7-17.

3. Kumar R, Cohen WR, Silva P, Epstein FH. Elevated 1,25-dihydroxyvitamin D plasma levels in normal human pregnancy and lactation. J Clin Invest 1979;63(2):342-4.

4. Robins SP. Collagen crosslinks in metabolic bone disease. Acta Orthop Scand Suppl. 1995;266:171-5.

5. Heaney RP. Vitamin D: how much do we need, and how much is too much? Osteoporos Int. 2000;11(7):553-5.

6. Park H, Brannon PM, West AA, Yan J, Jiang X, Perry CA, Malysheva O, Mehta S, Caudill MA. Maternal vitamin D biomarkers are associated with maternal and fetal bone turnover among pregnant women consuming controlled amounts of vitamin D, calcium, and phosphorus. Bone. 2017;95:183-91.

7. Thiering E, Bruske I, Kratzsch J, Hofbauer LC, Berdel D, von Berg A, Lehmann I, Hoffmann B, Bauer CP, Koletzko S, et al. Associations between serum 25-hydroxyvitamin D and bone turnover markers in a population based sample of German children. Sci Rep. 2015;5:18138.

8. Haliloglu B, Ilter E, Aksungar FB, Celik A, Coksuer H, Gunduz T, Yucel E, Ozekici U. Bone turnover and maternal 25(OH) vitamin D3 levels during pregnancy and the postpartum period: should routine vitamin D supplementation be increased in pregnant women? Eur J Obstet Gynecol Reprod Biol. 2011;158(1):24-7.

9. O'Brien EC, Kilbane MT, McKenna MJ, Segurado R, Geraghty AA, McAuliffe FM. Calcium intake in winter pregnancy attenuates impact of vitamin D inadequacy on urine NTX, a marker of bone resorption. Eur J Nutr. 2018;57(3):1015-23.

10. Black AJ, Topping J, Durham B, Farquharson RG, Fraser WD. A detailed assessment of alterations in bone turnover, calcium homeostasis, and bone density in normal pregnancy. J Bone Miner Res. 2000;15(3):557-63.

11. Cross NA, Hillman LS, Allen SH, Krause GF, Vieira NE. Calcium homeostasis and bone metabolism during pregnancy, lactation, and postweaning: a longitudinal study. Am J Clin Nutr. 1995;61(3):514-23.

12. Gallacher SJ, Fraser WD, Owens OJ, Dryburgh FJ, Logue FC, Jenkins A, Kennedy J, Boyle IT. Changes in calciotrophic hormones and biochemical markers of bone turnover in normal human pregnancy. Eur J Endocrinol. 1994;131(4):369-74.

13. Kaur M, Godber IM, Lawson N, Baker PN, Pearson D, Hosking DJ. Changes in serum markers of bone turnover during normal pregnancy. AnnClinBiochem. 2003;40(Pt 5):508-13.

14. Moller UK, Streym S, Mosekilde L, Heickendorff L, Flyvbjerg A, Frystyk J, Jensen LT, Rejnmark L. Changes in calcitropic hormones, bone markers and insulin-like growth factor I (IGF-I) during pregnancy and postpartum: a controlled cohort study. Osteoporos Int. 2013;24(4):1307-20.

15. Paoletti AM, Orru M, Floris L, Guerriero S, Ajossa S, Romagnino S, Melis GB. Pattern of bone markers during pregnancy and their changes after delivery. Horm Res. 2003;59(1):21-9.

16. Ritchie LD, Fung EB, Halloran BP, Turnlund JR, Van Loan MD, Cann CE, King JC. A longitudinal study of calcium homeostasis during human pregnancy and lactation and after resumption of menses. Am J Clin Nutr. 1998;67(4):693-701.

17. Yamaga A, Taga M, Minaguchi H, Sato K. Changes in bone mass as determined by ultrasound and biochemical markers of bone turnover during pregnancy and puerperium: a longitudinal study. J Clin Endocrinol Metab. 1996;81(2):752-6.

18. Harvey NC, Javaid K, Bishop N, Kennedy S, Papageorghiou AT, Fraser R, Gandhi SV, Schoenmakers I, Prentice A, Cooper C. MAVIDOS Maternal Vitamin D Osteoporosis Study: study protocol for a randomized controlled trial. The MAVIDOS Study Group. Trials. 2012;13:13.

19. Cooper C, Harvey NC, Bishop NJ, Kennedy S, Papageorghiou AT, Schoenmakers I, Fraser R, Gandhi SV, Carr A, D'Angelo S, et al. Maternal gestational vitamin D supplementation and offspring bone health (MAVIDOS): a multicentre, double-blind, randomised placebo-controlled trial. Lancet Diabetes Endocrinol. 2016;4(5):393-402.

20. Curtis EM, Krstic N, Cook E, D'Angelo S, Crozier SR, Moon RJ, Murray R, Garratt E, Costello P, Cleal J, et al. Gestational Vitamin D Supplementation Leads to Reduced Perinatal RXRA DNA Methylation: Results From the MAVIDOS Trial. J Bone Miner Res. 2019;34(2):231-40.

21. Jones KS, Assar S, Harnpanich D, Bouillon R, Lambrechts D, Prentice A, Schoenmakers I. 25(OH)D2 half-life is shorter than 25(OH)D3 half-life and is influenced by DBP concentration and genotype. J Clin Endocrinol Metab. 2014;99(9):3373-81.

22. Sempos CT, Vesper HW, Phinney KW, Thienpont LM, Coates PM. Vitamin D status as an international issue: national surveys and the problem of standardization. Scand J Clin Lab Invest Suppl. 2012;243:32-40.

23. Eastell R, Szulc P. Use of bone turnover markers in postmenopausal osteoporosis. The Lancet Diabetes & Endocrinology. 2017;5(11):908-23.

24. Naylor KE, Jacques RM, Paggiosi M, Gossiel F, Peel NF, McCloskey EV, Walsh JS, Eastell R. Response of bone turnover markers to three oral bisphosphonate therapies in postmenopausal osteoporosis: the TRIO study. Osteoporos Int. 2016;27(1):21-31.

25. Aickin M. Dealing with change: using the conditional change model for clinical research. The Permanente journal. 2009;13(2):80-4.

26. Ross AC, Manson JE, Abrams SA, Aloia JF, Brannon PM, Clinton SK, Durazo-Arvizu RA, Gallagher JC, Gallo RL, Jones G, et al. The 2011 report on dietary reference intakes for calcium and vitamin D from the Institute of Medicine: what clinicians need to know. The Journal of clinical endocrinology and metabolism. 2011;96(1):53-8.

27. Ó Breasail M, Ward KA, Schoenbuchner SM, Ceesay M, Mendy M, Jarjou LM, Moore SE, Prentice A. Pregnancy-Related Change in pQCT and Bone Biochemistry in a Population With a Habitually Low Calcium Intake. J Bone Miner Res. 2021.

28. Moller UK, Vieth Streym S, Mosekilde L, Rejnmark L. Changes in bone mineral density and body composition during pregnancy and postpartum. A controlled cohort study. Osteoporos Int. 2012;23(4):1213-23.

29. Ó Breasail M, Prentice A, Ward K. Pregnancy-Related Bone Mineral and Microarchitecture Changes in Women Aged 30 to 45 Years. J Bone Miner Res. 2020;35(7):1253-62.

30. Song SY, Kim Y, Park H, Kim YJ, Kang W, Kim EY. Effect of parity on bone mineral density: A systematic review and meta-analysis. Bone. 2017;101:70-6.

31. Qvist P, Christgau S, Pedersen BJ, Schlemmer A, Christiansen C. Circadian variation in the serum concentration of C-terminal telopeptide of type I collagen (serum CTx): effects of gender, age, menopausal status, posture, daylight, serum cortisol, and fasting. Bone. 2002;31(1):57-61.

32. Javaid MK, Crozier SR, Harvey NC, Taylor P, Inskip HM, Godfrey KM, Cooper C. Maternal and seasonal predictors of change in calcaneal quantitative ultrasound during pregnancy. J ClinEndocrinolMetab. 2005;90(9):5182-7.

33. Turner M, Barre PE, Benjamin A, Goltzman D, Gascon-Barre M. Does the maternal kidney contribute to the increased circulating 1,25-dihydroxyvitamin D concentrations during pregnancy? Miner Electrolyte Metab. 1988;14(4):246-52.

34. Lieben L, Stockmans I, Moermans K, Carmeliet G. Maternal hypervitaminosis D reduces fetal bone mass and mineral acquisition and leads to neonatal lethality. Bone.57(1):123-31.

35. Kovacs CS, Lanske B, Hunzelman JL, Guo J, Karaplis AC, Kronenberg HM. Parathyroid hormone-related peptide (PTHrP) regulates fetal-placental calcium transport through a receptor distinct from the PTH/PTHrP receptor. Proc Natl Acad Sci U S A. 1996;93(26):15233-8.

36. Simmonds CS, Karsenty G, Karaplis AC, Kovacs CS. Parathyroid hormone regulates fetal‐placental mineral homeostasis. Journal of Bone and Mineral Research. 2010;25(3):594-605.

37. Riccardi D, Brennan SC, Chang W. The extracellular calcium-sensing receptor, CaSR, in fetal development. Best Practice & Research Clinical Endocrinology & Metabolism.27(3):443-53.

38. Sanz-Salvador L, Garcia-Perez MA, Tarin JJ, Cano A. Bone metabolic changes during pregnancy: a period of vulnerability to osteoporosis and fracture. Eur J Endocrinol. 2015;172(2):R53-65.

39. European Food Safety Authority. Scientific opinion on dietary reference values for vitamin D. Parma, Italy: European Food Safety Authority. 2016.

40. Ettinger AS, Lamadrid-Figueroa H, Mercado-Garcia A, Kordas K, Wood RJ, Peterson KE, Hu H, Hernandez-Avila M, Tellez-Rojo MM. Effect of calcium supplementation on bone resorption in pregnancy and the early postpartum: a randomized controlled trial in Mexican women. Nutr J. 2014;13(1):116.

41. Nahas-Neto J, Cangussu LM, Orsatti CL, Bueloni-Dias FN, Poloni PF, Schmitt EB, Nahas EAP. Effect of isolated vitamin D supplementation on bone turnover markers in younger postmenopausal women: a randomized, double-blind, placebo-controlled trial. Osteoporosis International. 2018;29(5):1125-33.

42. Madar AA, Knutsen KV, Stene LC, Brekke M, Lagerlov P, Meyer HE, Macdonald HM. Effect of vitamin D3-supplementation on bone markers (serum P1NP and CTX): A randomized, double blinded, placebo controlled trial among healthy immigrants living in Norway. Bone Rep. 2015;2:82-8.

43. Macdonald HM, Wood AD, Aucott LS, Black AJ, Fraser WD, Mavroeidi A, Reid DM, Secombes KR, Simpson WG, Thies F. Hip bone loss is attenuated with 1000 IU but not 400 IU daily vitamin D3: a 1-year double-blind RCT in postmenopausal women. J Bone Miner Res. 2013;28(10):2202-13.

44. Marques EA, Gudnason V, Lang T, Sigurdsson G, Sigurdsson S, Aspelund T, Siggeirsdottir K, Launer L, Eiriksdottir G, Harris TB. Association of bone turnover markers with volumetric bone loss, periosteal apposition, and fracture risk in older men and women: the AGES-Reykjavik longitudinal study. Osteoporos Int. 2016;27(12):3485-94.

45. Chavassieux P, Portero-Muzy N, Roux JP, Garnero P, Chapurlat R. Are Biochemical Markers of Bone Turnover Representative of Bone Histomorphometry in 370 Postmenopausal Women? J Clin Endocrinol Metab. 2015;100(12):4662-8.

46. Garnero P, Sornay-Rendu E, Chapuy MC, Delmas PD. Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis. J Bone Miner Res. 1996;11(3):337-49.

47. Takaoka N, Nishida K, Sairenchi T, Umesawa M, Noguchi R, Someya K, Kobashi G. Changes in vitamin D status considering hemodilution factors in Japanese pregnant women according to trimester: A longitudinal survey. PLOS ONE. 2020;15(10):e0239954.

48. Naylor KE, Iqbal P, Fledelius C, Fraser RB, Eastell R. The effect of pregnancy on bone density and bone turnover. J Bone Miner Res. 2000;15(1):129-37.

49. Kovacs CS. The Skeleton Is a Storehouse of Mineral That Is Plundered During Lactation and (Fully?) Replenished Afterwards. J Bone Miner Res. 2017;32(4):676-80.

**Table 1:** Characteristics of MAVIDOS mothers with a measurement of CTX available in early or late pregnancy, in the study overall, and in the placebo group and cholecalciferol supplemented group separately, n = total number of participants with available data, N = number with characteristic.

|  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **All** | | | **Placebo** | | | **Cholecalciferol 1000 IU/day** | | |
| **Baseline characteristic** | **n** | **Mean** | **SD** | **n** | **Mean** | **SD** | **n** | **Mean** | **SD** |
| Age 1 | 607 | 30.4 | 5.2 | 296 | 30.4 | 5.3 | 311 | 30.3 | 5.3 |
| Height (cm) 1 | 602 | 165.4 | 6.5 | 292 | 165.5 | 6.7 | 310 | 165.2 | 6.4 |
| Weight (kg) 1 | 607 | 71.8 | 15.0 | 296 | 72.8 | 14.4 | 311 | 70.8 | 15.5 |
| Pregnancy weight gain (kg)2 | 536 | 9.5 | 3.6 | 264 | 9.3 | 3.7 | 272 | 9.7 | 3.4 |
| 25(OH)D at 14 weeks (nmol/l) | 630 | 44.6 | 16.2 | 312 | 44.1 | 16.1 | 318 | 45.0 | 16.3 |
| 25(OH)D at 34 weeks (nmol/l) | 561 | 54.2 | 23.6 | 282 | 42.5 | 20.6 | 279 | 66.0 | 20.4 |
| Adjusted calcium at 14 weeks (mmol/l) | 630 | 2.38 | 0.08 | 312 | 2.38 | 0.09 | 318 | 2.37 | 0.07 |
| Adjusted calcium at 34 weeks (mmol/l) | 560 | 2.34 | 0.11 | 280 | 2.34 | 0.12 | 280 | 2.34 | 0.10 |
|  | **n** | **Median** | **IQR** | **n** | **Median** | **IQR** | **n** | **Median** | **IQR** |
| BMI (kg/m2) 1 | 602 | 24.9 | 22.5-28.6 | 292 | 25.5 | 22.9-29.5 | 310 | 24.4 | 22.3-28.1 |
|  | **n** | **N** | **%** | **n** | **N** | **%** | **n** | **N** | **%** |
| First Pregnancy | 604 | 269 | 44.5 | 294 | 134 | 45.6 | 310 | 135 | 43.5 |
| White (Caucasian) ethnicity | 604 | 574 | 95.0 | 296 | 285 | 96.3 | 308 | 289 | 93.8 |
| A Level or higher qualification | 602 | 450 | 74.8 | 293 | 214 | 73.0 | 309 | 236 | 76.4 |
| Smoker 1 | 605 | 54 | 8.9 | 295 | 27 | 9.2 | 310 | 27 | 8.7 |
| More than one hour strenuous exercise per week 1 | 553 | 79 | 14.3 | 270 | 33 | 12.2 | 283 | 46 | 16.3 |

1 Characteristics at early pregnancy study visit; 2 pregnancy weight gain = 34 week maternal weight – 14 week maternal weight

**Table 2:** Maternal urinary CTX in early (EP, 14 weeks) and late pregnancy (LP, 34 weeks) and conditional change in CTX from early to late pregnancy, in all mothers in the MAVIDOS trial CTX sub-study with a measure of early or late pregnancy CTX, and in the placebo group and cholecalciferol 1000 IU supplemented groups separately; all mothers with a measure of both early and late pregnancy CTX, and in the placebo group and cholecalciferol 1000 IU supplemented groups separately. Change in CTX is calculated with a regression model, 34 week CTX as dependent variable and adjusting for 14 week CTX, absolute change in CTX is also shown. Participants are further stratified according to vitamin D sufficiency (≥50nmol/l or insufficiency <50nmol/l) in early pregnancy.

|  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **All** | | | **Placebo** | | | **Cholecalciferol 1000 IU/day** | | | **p-value** | |
|  | **n** | **Median** | **IQR** | **n** | **Median** | **IQR** | **n** | **Median** | **IQR** |  |
| **Participants with EP or LP CTX measures** | | | | | | | | | | |
| **EP CTX**  (µg/mmol creatinine) | 493 | 219.4 | 154.7, 306.4 | 242 | 223.8 | 155.0, 308.6 | 251 | 217.5 | 154.5, 305.2 | N/A |
| **LP CTX**  (µg/mmol creatinine) | 498 | 437.4 | 292.3, 633.0 | 252 | 445.3 | 317.6, 657.3 | 246 | 420.0 | 252.2, 608.5 | 0.06 |
| **Participants with both EP and LP CTX measures** | | | | | | | | | | |
| **EP CTX**  (µg/mmol creatinine) | 372 | 223.0 | 159.5, 316.4 | 188 | 223.6 | 153.6, 311.8 | 184 | 222.3 | 169.2, 319.8 | N/A |
| **LP CTX**  (µg/mmol creatinine) | 372 | 429.6 | 291.0, 660.6 | 188 | 449.7 | 327.3, 687.2 | 184 | 419.3 | 238.9, 629.9 | 0.03 |
|  | **n** | **Mean** | **SD** | **n** | **Mean** | **SD** | **n** | **Mean** | **SD** | **p-value** |
| **Δ CTX** (z score) |  |  |  | 188 | 0.16 | 0.92 | 184 | -0.16 | 1.06 | <0.01 |
| **Δ CTX** (absolute) |  |  |  | 188 | 258.1 | 322.1 | 184 | 214.5 | 316.7 | 0.19 |
| **Vitamin D sufficient women, baseline 25(OH)D ≥50nmol/l** | | | | | | | | | | |
|  | **All** | | | **Placebo** | | | **Cholecalciferol 1000 IU/day** | | | **p-value** |
|  | **n** | **Median** | **IQR** | **n** | **Median** | **IQR** | **n** | **Median** | **IQR** |  |
| **EP CTX**  (µg/mmol creatinine) | 168 | 232.8 | 167.0, 317.6 | 81 | 239.3 | 175.2, 326.9 | 87 | 225.3 | 163.4, 303.4 | N/A |
| **LP CTX**  (µg/mmol creatinine) | 161 | 409.1 | 286.3, 573.2 | 75 | 398.7 | 300.0, 573.2 | 86 | 414.4 | 265.8, 604.8 | 0.96 |
|  | **n** | **Mean** | **SD** | **n** | **Mean** | **SD** | **n** | **Mean** | **SD** | **p-value** |
| **Δ CTX** (z score) |  |  |  | 61 | -0.14 | 0.92 | 61 | -0.17 | 1.11 | 0.85 |
| **Vitamin D insufficient women, baseline 25(OH)D <50nmol/l** | | | | | | | | | | |
|  | **All** | | | **Placebo** | | | **Cholecalciferol 1000 IU/day** | | | **p-value** |
|  | **n** | **Median** | **IQR** | **n** | **Median** | **IQR** | **n** | **Median** | **IQR** |  |
| **EP CTX**  (µg/mmol creatinine) | 320 | 215.8 | 142.7, 303.2 | 159 | 216.0 | 148.0, 299.6 | 161 | 215.7 | 139.7, 307.5 | N/A |
| **LP CTX**  (µg/mmol creatinine) | 335 | 444.5 | 293.2, 660.4 | 176 | 459.7 | 333.8, 675.9 | 159 | 422.1 | 249.5, 633.0 | <0.01 |
|  | **n** | **Mean** | **SD** | **n** | **Mean** | **SD** | **n** | **Mean** | **SD** | **p-value** |
| **Δ CTX** (z score) |  |  |  | 126 | 0.28 | 0.89 | 123 | -0.15 | 1.04 | <0.01 |

p-values represent outcomes of tests for differences between the placebo group and vitamin D supplemented group (Rank Sum tests for LP CTX, t tests for Δ CTX (z score)). EP = 14 weeks’ gestation; LP = 34 weeks’ gestation; ΔCTX = conditional change in CTX (LP CTX adjusted for EP CTX), SD.

**Table 3:** Univariate maternal determinants of CTX in early and late pregnancy (Fisher-Yates Scores), standard deviation increase per unit change in maternal predictor, in those with both an early and late pregnancy measure.

|  |  |  |  |
| --- | --- | --- | --- |
|  | **EP CTX**  **(14 weeks’ gestation)** | **LP CTX 1**  **(34 weeks’ gestation)** | **Δ CTX 1, 3** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| **Exposure** | **n** | **β 2** | **95% CI** | **p-value** | **n** | **β 2** | **95% CI** | **p-value** | **n** | **β** | **95% CI** | **p-value** |

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
| Maternal age (years) | 493 | -0.03 | (-0.05,-0.01) | <0.001 | 469 | -0.03 | (-0.04,-0.01) | 0.01 | 372 | -0.02 | (-0.037,0.002) | 0.07 |
| Strenuous exercise (> 1 hr /week, Y/N) | 440 | -0.10 | (-0.36,0.16) | 0.47 | 425 | -0.11 | (-0.40,0.18) | 0.47 | 329 | -0.17 | (-0.50,0.16) | 0.31 |
| Smoking in early pregnancy (Y/N) | 491 | 0.36 | (0.05,0.68) | 0.03 | 467 | -0.20 | (-0.53,0.13) | 0.24 | 370 | -0.20 | (-0.57,0.17) | 0.30 |
| Parity (One or more, Y/N) | 491 | -0.48 | (-0.66,-0.31) | <0.001 | 467 | -0.33 | (-0.52,-0.15) | <0.001 | 371 | -0.11 | (-0.32,0.09) | 0.28 |
| Caucasian ethnicity (Y/N) | 490 | 0.17 | (-0.25,0.58) | 0.44 | 466 | 0.23 | (-0.21,0.67) | 0.31 | 369 | 0.33 | (-0.20,0.86) | 0.22 |
| Weight (kg) | 493 | -0.01 | (-0.01,0.00) | 0.07 | 469 | 0.002 | (-0.004,0.008) | 0.50 | 372 | 0.01 | (-0.001,0.013) | 0.12 |
| Height (cm) | 488 | -0.01 | (-0.03,0.00) | 0.05 | 465 | -0.02 | (-0.03,-0.01) | 0.004 | 368 | -0.01 | (-0.029,0.004) | 0.13 |
| BMI (kg/cm2) | 488 | -0.01 | (-0.03,0.01) | 0.21 | 465 | 0.02 | (-0.001,0.034) | 0.07 | 368 | 0.02 | (0.001,0.041) | 0.04 |
| 14 week 25(OH)D (nmol/l) | 488 | 0.004 | (-0.001,0.009) | 0.14 | 496 | -0.004 | (-0.010,0.001) | 0.13 | 371 | -0.01 | (-0.014,-0.001) | 0.03 |
| 14 week Calcium (mmol/l) | 488 | 0.53 | (-0.56,1.62) | 0.34 | 496 | 0.67 | (-0.36,1.70) | 0.20 | 371 | 1.14 | (-0.09,2.38) | 0.07 |
| 34 wk. 25(OH)D (nmol/l) |  |  |  |  | 489 | -0.001 | (-0.016,0.003) | 0.55 | 364 | -0.003 | (-0.009,0.002) | 0.19 |
| 34 wk. calcium (mmol/l) |  |  |  |  | 488 | 0.15 | (-0.63,0.92) | 0.71 | 363 | 0.19 | (-0.74,1.11) | 0.70 |
| Change in 25(OH)D from 14 to 34 wks. (nmol/l) |  |  |  |  | 487 | 0.001 | (-0.003,0.005) | 0.60 | 363 | 0.001 | (-0.004,0.006) | 0.77 |
| Vit D supplemented group (Y/N) |  |  |  |  | 498 | -0.18 | (-0.35,-0.00) | 0.05 | 372 | -0.32 | (-0.52,-0.11) | 0.002 |
| Season of delivery, summer (proxy for season of measurement) | 438 | 0.02 | (-0.16,0.21) | 0.81 | 488 | 0.07 | (-0.11,0.25) | 0.44 | 366 | 0.07 | (-0.14,0.27) | 0.52 |

1 adjusted for treatment group, except when associations between vitamin D supplemented group and CTX are being tested. 2 standard deviation change in urinary CTX (Fisher Yates Score) per unit exposure. 3 conditional change in CTX (LP CTX adjusted for EP CTX), as Z-score.

**Table 4:** Associations between EP or LP 25(OH)D, and LP CTX (Fisher-Yates score) or conditional change in CTX (Δ CTX, LP CTX adjusted for EP CTX), SD.

|  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- |
|  | **Exposure** | **EP 25(OH)D** | | **LP 25(OH)D** | |
|  | **Outcome** | **LP CTX1** | **Δ CTX 2** | **LP CTX**1 | **Δ CTX 2** |
| Adjusted for season | **n** | 486 | 365 | 479 | 358 |
| **β** | -0.004 | -0.007 | -0.004 | -0.008 |
| **95%CI** | (-0.010, 0.002) | (-0.013, -0.001) | (-0.008, -0.001) | (-0.012, -0.003) |
| **p-value** | 0.156 | 0.049 | 0.056 | 0.001 |
| Adjusted for season of delivery, maternal age, parity, BMI, smoking and height | **n** | 450 | 358 | 443 | 351 |
| **β** | -0.003 | -0.06 | -0.004 | -0.008 |
| **95%CI** | (-0.009, 0.003) | (-0.013, 0.001) | (-0.008, -0.001) | (-0.012, -0.003) |
| **p-value** | 0.396 | 0.097 | 0.054 | 0.002 |

1 difference in urinary CTX per unit exposure (Fisher-Yates), SD; 2 conditional change in CTX (LP CTX adjusted for EP CTX), SD.

**Table 5:** Associations between late pregnancy urine CTX (Fisher-Yates transformed, expressed in standard deviations) or conditional change in CTX (LP CTX adjusted for EP CTX, as Z-score), in the vitamin D supplemented, placebo groups, or combined, and maternal lumbar spine and total hip area, bone mineral content (BMC) and bone mineral density (BMD). Models are adjusted for maternal age, parity, smoking and BMI at baseline.

|  |  |  |  |  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  | **Total population** | | | | **Placebo** | | | | **Cholecalciferol 1000 IU/day** | | | |
| **LP CTX** | **n** | **** | **95% CI** | **p-value** | **n** | **** | **95% CI** | **p-value** | **n** | **** | **95% CI** | **p-value** |
| **Lumbar spine** |  |  |  |  |  |  |  |  |  |  |  |  |
| Bone area (cm2) | 283 | -0.34 | (-0.96,0.29) | 0.29 | 135 | -0.73 | (-1.697,0.235) | 0.14 | 148 | -0.08 | (-0.92,0.80) | 0.86 |
| BMC (g) | 283 | -1.17 | (-2.29,-0.04) | 0.04 | 135 | -1.30 | (-2.972,0.377) | 0.13 | 148 | -1.11 | (-2.69,0.46) | 0.17 |
| aBMD (g/cm2) | 283 | -0.015 | (-0.027,-0.003) | 0.02 | 135 | -0.009 | (-0.028,0.010) | 0.34 | 148 | -0.019 | (-0.036,-0.003) | 0.03 |
| **Total hip** |  |  |  |  |  |  |  |  |  |  |  |  |
| Bone area (cm2) | 279 | -0.32 | (-0.70,0.06) | 0.10 | 133 | -0.32 | (-0.94,0.29) | 0.30 | 146 | -0.37 | (-0.85,0.11) | 0.13 |
| BMC (g) | 279 | -0.68 | (-1.21,-0.14) | 0.01 | 133 | -0.51 | (-1.31,0.30) | 0.22 | 146 | -0.87 | (-1.62,-0.13) | 0.02 |
| aBMD (g/cm2) | 279 | -0.012 | (-0.02,-0.00) | 0.05 | 133 | -0.004 | (-0.022,0.013) | 0.61 | 146 | -0.017 | (-0.033,-0.002) | 0.03 |
| **Δ CTX** | **Total population** | | |  | **Placebo** | | |  | **Cholecalciferol 1000 IU/day** | | |  |
|  | **n** | **** | **95% CI** | **p-value** | **n** | **** | **95% CI** | **p-value** | **n** | **** | **95% CI** | **p-value** |
| **Lumbar spine** |  |  |  |  |  |  |  |  |  |  |  |  |
| Bone area (cm2) | 226 | -0.23 | (-0.92,0.45) | 0.50 | 109 | -0.86 | (-1.93,0.22) | 0.12 | 117 | 0.22 | (-0.72,1.17) | 0.64 |
| BMC (g) | 226 | -0.72 | (-1.98,0.54) | 0.26 | 109 | -1.07 | (-2.98,0.84) | 0.27 | 117 | -0.66 | (-2.49,1.16) | 0.47 |
| aBMD (g/cm2) | 226 | -0.01 | (-0.02,0.01) | 0.22 | 109 | 0.00 | (-0.03,0.02) | 0.78 | 117 | -0.02 | (-0.037,0.003) | 0.10 |
| **Total hip** |  |  |  |  |  |  |  |  |  |  |  |  |
| Bone area (cm2) | 223 | -0.29 | (-0.70,0.12) | 0.16 | 108 | -0.32 | (-0.97,0.33) | 0.33 | 115 | -0.34 | (-0.87,0.20) | 0.21 |
| BMC (g) | 223 | -0.32 | (-0.92,0.29) | 0.31 | 108 | -0.24 | (-1.15,0.67) | 0.60 | 115 | -0.48 | (-1.35,0.38) | 0.27 |
| aBMD (g/cm2) | 223 | 0.00 | (-0.01,0.01) | 0.83 | 108 | 0.003 | (-0.02,0.02) | 0.74 | 115 | -0.01 | (-0.03,0.01) | 0.47 |

**Table 6:** Associations between conditional change in pregnancy urine CTX (Δ CTX, expressed in standard deviations) in the vitamin D supplemented and placebo groups combined (total population), and neonatal DXA outcomes at the total body and total spine after adjustment for sex, baby age at DXA scan and gestational age at birth.

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Δ CTX** | **Total population** | | | |
|  | **n** | **** | **95% CI** | **p-value** |
| **Neonatal total body DXA** |  |  |  |  |
| Total area (cm) | 321 | 4.781 | (1.567, 7.995) | 0.004 |
| Total BMC (g) | 321 | 1.754 | (0.798, 2.711) | <0.001 |
| Total BMD (g/cm2) | 321 | 0.003 | (0.001, 0.005) | 0.002 |
|  |  |  |  |  |
| **Neonatal total spine DXA** |  |  |  |  |
| Total spine area (cm) | 290 | 0.140 | (0.027, 0.252) | 0.015 |
| Total spine BMC (g) | 290 | 0.071 | (0.022, 0.120) | 0.005 |
| Total spine BMD (g/cm2) | 290 | 0.004 | (0.000, 0.008) | 0.038 |

Δ CTX = conditional change in CTX (LP CTX adjusted for EP CTX), SD.

**Figure legends**

**Figure 1**

Frequency distribution of maternal urinary CTX (g/mmol creatinine) in early (14 weeks’ gestation, median 219.4, IQR 154.7, 306.4, n=493) and late pregnancy (34 weeks’ gestation; median 437.4, IQR 292.3, 633.0; n=498) in all mothers with a measurement of CTX.

**Figure 2**

Late pregnancy urinary CTX (shown in quarters of the distribution, SD) and A) maternal postpartum lumbar spine area, BMC and aBMD (n =283) and B) total hip area, BMC and aBMD (n = 279) assessed by DXA (in both groups combined).

*CTX divided into quarters of the distribution: -1.5 SD to -0.7 SD; -0.7 SD to -0.2 SD, -0.2 SD to +0.5 SD, +0.5 SD or above*